research NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.
Search
forResearch
5 / 1000+ results
research Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
Adding a second method to PROTACs could improve cancer treatment.
research PROTACs in cancer therapy: targeted degradation of GPX4, PARP and epigenetic regulators
PROTACs show promise in cancer treatment by effectively degrading specific harmful proteins.
research Peptide-Based PROTACs: Transitioning from Static Paradigm to a Dynamic Landscape within Targeted Protein Degradation
Peptide-based PROTACs show promise in targeting hard-to-treat proteins, especially for cancer therapy.
research Clinical Translation of Targeted Protein Degraders
Targeted protein degraders show promise in treating cancer but need to target more diverse proteins.
Community Join
5 / 71 resultscommunity Protac degradation of the androgen receptor in mice shows good efficacy and no systemic drug could be found
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
community End of Hair loss ( AGA ) ? Since they produce it in china probably we don’t need to wait other 10 yrs😁
GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.
community AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community About GT20029's Efficacy and Strength
The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.
Learn
2 / 801 resultslearn Tricopper peptides
learn ACETYL TETRAPEPTIDE-2
Clinics
6 / 7 results- 29Hair TransplantDr Prateek Tiwari's Skin Hub Derma, Hair & Laser ClinicUjjain, Madhya Pradesh · IN
- 70
Hair TransplantAhmet Barutcu Saç Ekimi / Hair TransplantAnkara · TR - 58
Hair Loss TreatmentsDermatologyDr. Pratik Shivhare Nirvana Skin & Hair ClinicJhānsi, Uttar Pradesh · IN - 21Hair Loss TreatmentsDr. Prateek JainGwalior, Madhya Pradesh · IN
- 8
Hair TransplantDr. Ümit Borataçİstanbul · TR - 19Hair Loss TreatmentsTerapia Capilar by Silvinha Velloso, plasma pen, especialista em Ruivas, produção cabelo e maquiagemGoiânia, GO · BR
Experts
6 / 6 results- 71
Hair Transplant SurgeonDr. Cosmin Moculescu, MD
Bucharest, Romania
- 73
DermatologistDr. Prateek Sondhi, MD, MBBS
Delhi, Delhi, India
- 70
DermatologistDr. Pratik Shivhare, MD, MBBS
Jhānsi, Uttar Pradesh, India
- 84
DermatologistDr. Pratik Sheth, MD
Rājkot, Gujarat, India
- 32
DermatologistPratichya Thapa
Bharatpur, Nepal
- 70
Hair Transplant SurgeonAhmet Barutcu
Ankara, Türkiye